Wall Street is positive on Brickell Biotech Inc (BBI). On average, analysts give Brickell Biotech Inc a Strong Buy rating. The average price target is $5, which means analysts expect the stock to increase by 1251.35% over the next twelve months. That average ranking earns Brickell Biotech Inc an Analyst Rating of 75, which is better than 75% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating BBI a Strong Buy today. Find out what this means to you and get the rest of the rankings on BBI!